agilon health inc

AGL is in a corrective phase with sequential lower highs and lower lows beneath the 9- and 20-day EMAs. Medium-term bias is bearish under Stage 3, and short-term timing unfavorable as price rejects minor EMAs. Execution favors selling now into rallies up to the EMA zone while supply remains dominant.

• ↑Q2 revenue grew 7% YoY to $1.5B; medical margin turned positive at $197M vs –$53M prior.
• ↑Adjusted EBITDA of $70M in Q2 vs a –$83M loss last year.
• ↓Negative profitability factor and negative earnings yield raise valuation concerns.